Table 3 Model parameter estimates and data sources
Parameter | France | Germany | Italy | Spain | Model code color | |
|---|---|---|---|---|---|---|
Proportion non-small cell cases at diagnosis (%) | 83.1 | 81.2 | 84.8 | 86.6 | Orange | |
Source | [34] | [35] | [32] | [36] | ||
Squamous (%) | 38.3 | 35.9 | 32.2 | 40.5 | ||
Non-squamous (%) | 61.7 | 64.1 | 67.8 | 59.5 | ||
Source | [32] | |||||
Stage at diagnosis (%) | I | 7.5 | 13.7 | 10.0 | 7.4 | Purple |
II | 7.9 | 8.3 | 5.9 | 6.2 | ||
III | 25.2 | 33.4 | 23.3 | 33.4 | ||
Proportion of stage III patients who are IIIb (%) | 49.6 | 60.8 | 63.1 | 68.3 | ||
IV | 52.9 | 41.3 | 53.5 | 48.5 | ||
Unknown | 6.5 | 3.3 | 7.3 | 4.5 | ||
Source | [37] | |||||
Five-year rate of distant recurrence of the tumor from stage (%) | I | 25.8 | Blue | |||
II | 45.8 | |||||
IIIa | 44.8 | |||||
Source | [38] | |||||
Median OS (months) | Squamous NSCLC | 6.0 | ||||
Source | [10] | |||||
Non-squamous NSCLC | 9.4 | |||||
Source | [11] | |||||
Proportion of advanced NSCLC patients referred to BSC (%) | 11.7% | Aqua blue | ||||
Proportion eligible for systemic treatment (%) | 88.3% | |||||
Source | [36] | |||||
Proportion of squamous patients receiving (%) | First LOT | 77.9 | 89.2 | 90.0 | 97.5 | Green |
Second LOT | 28.6 | 37.8 | 42.2 | 39.2 | ||
Third LOT | 10.4 | 9.5 | 10.0 | 2.5 | ||
Proportion of non-squamous patients receiving (%) | First LOT | 89.5 | 93.8 | 92.3 | 99.1 | |
Second LOT | 46.8 | 52.3 | 57.7 | 54.3 | ||
Third LOT | 12.9 | 18.5 | 8.7 | 16.4 | ||
Source | [13] | |||||